Last Close
Feb 26  •  10:03AM ET
5.45
Dollar change
+0.03
Percentage change
0.55
%
IndexRUT P/E- EPS (ttm)-2.02 Insider Own39.43% Shs Outstand49.89M Perf Week18.22%
Market Cap325.97M Forward P/E- EPS next Y-0.26 Insider Trans2.26% Shs Float30.26M Perf Month4.41%
Enterprise Value337.40M PEG- EPS next Q-0.14 Inst Own22.91% Short Float3.76% Perf Quarter-1.80%
Income-72.25M P/S8.11 EPS this Y-35.57% Inst Trans5.17% Short Ratio6.40 Perf Half Y6.86%
Sales40.21M P/B- EPS next Y85.28% ROA-123.81% Short Interest1.14M Perf YTD-21.92%
Book/sh-0.54 P/C14.37 EPS next 5Y- ROE- 52W High7.95 -31.45% Perf Year-1.80%
Cash/sh0.38 P/FCF- EPS past 3/5Y- -175.42% ROIC-993.87% 52W Low3.42 59.36% Perf 3Y-46.15%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin83.12% Volatility9.03% 6.70% Perf 5Y-46.98%
Dividend TTM- EV/Sales8.39 EPS Y/Y TTM19.34% Oper. Margin-77.74% ATR (14)0.39 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.75 Sales Y/Y TTM49.52% Profit Margin-179.71% RSI (14)55.15 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio3.05 EPS Q/Q-693.54% SMA2010.53% Beta0.41 Target Price11.50
Payout- Debt/Eq- Sales Q/Q57.38% SMA50-5.00% Rel Volume0.51 Prev Close5.42
Employees110 LT Debt/Eq- EarningsMar 05 AMC SMA2004.83% Avg Volume177.82K Price5.45
IPOFeb 08, 2021 Option/ShortNo / Yes EPS/Sales Surpr.-546.03% -1.64% Trades Volume11,742 Change0.55%
Date Action Analyst Rating Change Price Target Change
Feb-13-25Initiated Lake Street Buy
Dec-17-24Initiated Cantor Fitzgerald Overweight $10
Nov-11-24Initiated ROTH MKM Buy $11
Oct-25-24Initiated Northland Capital Outperform $12.50
Sep-16-24Initiated Oppenheimer Outperform $10
May-30-24Initiated Canaccord Genuity Buy $12
Feb-25-26 04:05PM
Feb-20-26 08:00AM
Feb-19-26 04:01PM
Feb-09-26 09:00AM
Jan-14-26 12:00PM
07:00AM Loading…
Jan-12-26 07:00AM
Dec-04-25 04:01PM
Nov-18-25 08:00AM
Nov-14-25 12:04AM
Nov-13-25 05:15PM
04:01PM
Nov-12-25 07:29AM
07:10AM
Nov-11-25 04:05PM
Nov-10-25 08:00AM
07:00PM Loading…
Nov-06-25 07:00PM
Nov-05-25 06:15PM
Oct-30-25 08:00AM
Aug-28-25 08:00AM
Aug-13-25 03:12AM
Aug-12-25 05:10PM
04:01PM
Aug-11-25 07:00PM
09:37AM
08:00AM
Aug-07-25 07:40AM
Jul-30-25 04:05PM
Jul-29-25 04:05PM
Jul-24-25 05:58PM
Jun-23-25 05:30PM
08:00AM Loading…
Jun-04-25 08:00AM
May-30-25 07:00AM
May-16-25 03:01PM
May-15-25 08:10AM
07:00AM
May-12-25 07:15PM
04:30PM
07:45AM
May-08-25 06:45PM
Apr-30-25 08:15AM
08:00AM
Apr-10-25 11:33AM
Apr-09-25 08:47AM
Mar-30-25 08:02AM
Mar-27-25 02:02PM
08:40AM
07:30AM
Mar-26-25 08:00AM
Mar-06-25 08:00AM
Feb-03-25 04:05PM
08:00AM
Jan-23-25 08:00AM
Jan-10-25 08:30AM
Jan-09-25 08:00AM
Jan-08-25 08:00AM
Nov-14-24 08:00AM
Nov-13-24 07:27AM
Nov-11-24 07:00AM
Nov-07-24 07:00AM
Oct-31-24 08:00AM
Oct-14-24 04:05PM
Sep-26-24 07:00AM
Sep-23-24 07:00AM
Sep-14-24 01:52AM
Aug-15-24 08:00AM
Aug-01-24 07:00AM
Jul-01-24 04:00PM
Jun-26-24 05:45PM
Jun-03-24 07:00AM
May-24-24 06:05AM
May-15-24 12:53PM
08:00AM
May-07-24 07:00AM
May-06-24 04:58PM
Apr-30-24 04:35PM
Apr-01-24 12:53PM
09:33AM
08:00AM
Mar-26-24 08:00AM
Mar-21-24 08:00AM
Mar-11-24 05:15PM
Mar-07-24 07:00AM
Feb-29-24 07:00AM
Dec-14-23 07:00AM
Nov-14-23 12:27PM
08:00AM
Nov-07-23 04:05PM
Nov-04-23 02:25PM
Nov-03-23 12:00PM
Oct-25-23 09:05AM
Sep-06-23 07:00AM
Aug-10-23 04:05PM
Aug-02-23 05:00PM
Jun-12-23 07:00AM
Apr-20-23 07:00AM
Feb-21-23 07:00AM
Dec-07-22 09:26PM
Nov-14-22 04:24PM
Mar-14-22 02:32PM
Mar-10-22 08:11AM
TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patience DavidChief Financial OfficerFeb 23 '26Buy4.103,65714,994268,657Feb 23 04:08 PM
Gordon Gary B.DirectorFeb 23 '26Buy4.109,75640,0009,756Feb 23 04:08 PM
Valle WilliamDirectorFeb 23 '26Buy4.1030,487124,99730,487Feb 23 04:08 PM
Szela Mary TCEO and PresidentFeb 23 '26Buy4.1030,487124,997773,289Feb 23 04:08 PM
Stansky Michael PDirectorFeb 23 '26Buy4.10243,900999,990787,132Feb 23 04:08 PM
Stansky Michael PDirectorFeb 23 '26Buy4.10117,198480,512199,698Feb 23 04:08 PM
Cox Bryan F.Chief of ResearchMay 19 '25Sale5.184,76424,678119,415May 21 05:33 PM
Devlin JodiChief of Clinical OperationsMay 19 '25Sale5.184,76424,67852,764May 21 05:31 PM
Marshak RichardChief Commercial OfficerMay 19 '25Sale5.186,59734,17269,101May 21 05:30 PM
Stevens JenniferChief Regulatory OfficerMay 19 '25Sale5.188,70445,08777,640May 21 05:27 PM